Remove topic diabetes
article thumbnail

Grand Rounds June 23, 2023: Improving Delivery of Care for Chronic Kidney Disease, Diabetes and Hypertension (Miguel A. Vazquez, MD and George Oliver, MD, PhD)

Rethinking Clinical Trials

They presented on the topic of Improving Delivery of Care for Chronic Kidney Disease, Diabetes in Hypertension. The post Grand Rounds June 23, 2023: Improving Delivery of Care for Chronic Kidney Disease, Diabetes and Hypertension (Miguel A. Learn more about the Improving Chronic Disease Management with Pieces (ICD-Pieces trial.

article thumbnail

LyGenesis and Imagine Pharma partner for type 1 diabetes therapies development

Pharmaceutical Technology

Clinical-stage biotechnology firm LyGenesis has formed a joint research collaboration with Imagine Pharma to develop new cell therapies for type 1 diabetes (T1D). Topic sponsors are not involved in the creation of editorial content. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Phase Ib/IIa trial in diabetic macular oedema successfully completed  

Drug Discovery World

Exonate, an mRNA therapy company focused on treatments for diabetic complications, has announced that its lead ophthalmology asset, EXN407, has achieved its prespecified endpoints in a Phase Ib/IIa study. During the trial, EXN407 met all safety and pharmacokinetic parameters and displayed encouraging signals of biological activity.

Trials 52
article thumbnail

21 European countries unite in the EU Joint Action JACARDI to reduce the burden of cardiovascular diseases and diabetes

Sciensano

A new four-year project called the Joint Action on Cardiovascular Diseases and Diabetes ( JACARDI ) was launched in Rome on 27 November 2023. The prevalence of diabetes has also risen dramatically, with the number of adults living with the condition nearly doubling in the past decade, reaching 32.3 million in 2019.

article thumbnail

Oculis enters merger deal with European Biotech Acquisition

Pharmaceutical Technology

Oculis works on developing product candidates for areas with substantial medical needs, including diabetic macular oedema (DME), dry eye disease (DED) and glaucoma. OCS-02 is a topical anti-TNF alpha monoclonal antibody fragment, while OCS-05 is an activator of serum-glucocorticoid kinase 2.

article thumbnail

Vertex signs agreement to acquire ViaCyte for $320m

Pharmaceutical Technology

ViaCyte focuses on offering new stem cell-derived cell replacement therapies as a functional cure for type 1 diabetes (T1D). Topic sponsors are not involved in the creation of editorial content. Through the acquisition, Vertex plans to advance its potentially curative VX-880 programmes in T1D.

article thumbnail

Popularity of weight loss drugs soars, but weight stigma persists

Medical Xpress

Weight loss has always been a hot topic in the media, and now, with the rise in popularity of a class of drugs that induce weight loss, it's more controversial than ever.

Drugs 63